vs
Side-by-side financial comparison of Sonoma Pharmaceuticals, Inc. (SNOA) and Xos, Inc. (XOS). Click either name above to swap in a different company.
Xos, Inc. is the larger business by last-quarter revenue ($5.2M vs $4.3M, roughly 1.2× Sonoma Pharmaceuticals, Inc.). Sonoma Pharmaceuticals, Inc. runs the higher net margin — -18.8% vs -186.8%, a 168.0% gap on every dollar of revenue. On growth, Sonoma Pharmaceuticals, Inc. posted the faster year-over-year revenue change (22.0% vs -54.5%). Over the past eight quarters, Sonoma Pharmaceuticals, Inc.'s revenue compounded faster (12.5% CAGR vs -35.7%).
Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical firm focused on developing, manufacturing and selling dermatology and wound care products. It operates across North America, Europe and Asia, with offerings covering acne treatment, skin infection management, post-surgical wound recovery and chronic skin condition care for consumers and healthcare providers.
Xos, Inc. is an American manufacturer of commercial electric vehicles (EVs) and mobile EV chargers.
SNOA vs XOS — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.3M | $5.2M |
| Net Profit | $-819.0K | $-9.8M |
| Gross Margin | 37.9% | -50.5% |
| Operating Margin | -15.6% | -186.6% |
| Net Margin | -18.8% | -186.8% |
| Revenue YoY | 22.0% | -54.5% |
| Net Profit YoY | 11.7% | 48.6% |
| EPS (diluted) | $-0.48 | $-0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.3M | $5.2M | ||
| Q3 25 | $5.6M | $16.5M | ||
| Q2 25 | $4.0M | $18.4M | ||
| Q1 25 | $3.8M | $5.9M | ||
| Q4 24 | $3.6M | $11.5M | ||
| Q3 24 | $3.6M | $15.8M | ||
| Q2 24 | $3.4M | $15.5M | ||
| Q1 24 | $3.4M | $12.6M |
| Q4 25 | $-819.0K | $-9.8M | ||
| Q3 25 | $-534.0K | $2.1M | ||
| Q2 25 | $-1.2M | $-7.5M | ||
| Q1 25 | $-776.0K | $-10.2M | ||
| Q4 24 | $-928.0K | $-19.0M | ||
| Q3 24 | $-610.0K | $-10.5M | ||
| Q2 24 | $-1.1M | $-9.7M | ||
| Q1 24 | $-1.1M | $-11.0M |
| Q4 25 | 37.9% | -50.5% | ||
| Q3 25 | 37.8% | 15.3% | ||
| Q2 25 | 36.5% | 8.8% | ||
| Q1 25 | 40.7% | 20.6% | ||
| Q4 24 | 35.6% | -32.4% | ||
| Q3 24 | 38.0% | 18.1% | ||
| Q2 24 | 38.5% | 13.1% | ||
| Q1 24 | 31.7% | 22.1% |
| Q4 25 | -15.6% | -186.6% | ||
| Q3 25 | -6.0% | -42.4% | ||
| Q2 25 | -27.3% | -38.5% | ||
| Q1 25 | -17.5% | -157.7% | ||
| Q4 24 | -28.9% | -127.0% | ||
| Q3 24 | -23.7% | -61.4% | ||
| Q2 24 | -34.6% | -73.2% | ||
| Q1 24 | -41.0% | -81.1% |
| Q4 25 | -18.8% | -186.8% | ||
| Q3 25 | -9.5% | 12.9% | ||
| Q2 25 | -30.9% | -40.8% | ||
| Q1 25 | -20.7% | -173.3% | ||
| Q4 24 | -26.0% | -165.4% | ||
| Q3 24 | -17.0% | -66.6% | ||
| Q2 24 | -33.7% | -62.2% | ||
| Q1 24 | -31.0% | -87.1% |
| Q4 25 | $-0.48 | $-0.76 | ||
| Q3 25 | $-0.32 | $0.22 | ||
| Q2 25 | $-0.76 | $-0.91 | ||
| Q1 25 | $-0.23 | $-1.26 | ||
| Q4 24 | $-0.63 | $-2.34 | ||
| Q3 24 | $-0.59 | $-1.32 | ||
| Q2 24 | $-1.34 | $-1.23 | ||
| Q1 24 | $-3.00 | $-1.80 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.6M | $14.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.4M | $23.3M |
| Total Assets | $13.6M | $60.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.6M | $14.0M | ||
| Q3 25 | $3.0M | $14.1M | ||
| Q2 25 | $3.6M | $8.8M | ||
| Q1 25 | $5.4M | $4.8M | ||
| Q4 24 | $5.2M | $11.0M | ||
| Q3 24 | $4.1M | $8.4M | ||
| Q2 24 | $2.6M | $19.7M | ||
| Q1 24 | $3.1M | $46.2M |
| Q4 25 | $3.4M | $23.3M | ||
| Q3 25 | $3.8M | $31.1M | ||
| Q2 25 | $4.1M | $18.3M | ||
| Q1 25 | $4.4M | $24.8M | ||
| Q4 24 | $4.9M | $33.6M | ||
| Q3 24 | $5.4M | $50.8M | ||
| Q2 24 | $5.0M | $59.2M | ||
| Q1 24 | $6.1M | $67.8M |
| Q4 25 | $13.6M | $60.4M | ||
| Q3 25 | $13.9M | $73.8M | ||
| Q2 25 | $14.6M | $80.3M | ||
| Q1 25 | $13.7M | $87.7M | ||
| Q4 24 | $13.7M | $98.3M | ||
| Q3 24 | $13.7M | $120.5M | ||
| Q2 24 | $13.7M | $123.4M | ||
| Q1 24 | $14.7M | $135.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-764.0K | $2.4M |
| Free Cash FlowOCF − Capex | $-811.0K | — |
| FCF MarginFCF / Revenue | -18.6% | — |
| Capex IntensityCapex / Revenue | 1.1% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-3.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-764.0K | $2.4M | ||
| Q3 25 | $-635.0K | $3.1M | ||
| Q2 25 | $-2.0M | $4.6M | ||
| Q1 25 | $-95.0K | $-4.8M | ||
| Q4 24 | $565.0K | $3.3M | ||
| Q3 24 | $354.0K | $-11.5M | ||
| Q2 24 | $-912.0K | $-26.0M | ||
| Q1 24 | $152.0K | $-14.6M |
| Q4 25 | $-811.0K | — | ||
| Q3 25 | $-645.0K | — | ||
| Q2 25 | $-2.1M | — | ||
| Q1 25 | $-142.0K | — | ||
| Q4 24 | $563.0K | — | ||
| Q3 24 | $328.0K | $-11.7M | ||
| Q2 24 | $-917.0K | $-26.1M | ||
| Q1 24 | $134.0K | $-14.6M |
| Q4 25 | -18.6% | — | ||
| Q3 25 | -11.5% | — | ||
| Q2 25 | -52.8% | — | ||
| Q1 25 | -3.8% | — | ||
| Q4 24 | 15.8% | — | ||
| Q3 24 | 9.2% | -73.9% | ||
| Q2 24 | -27.0% | -168.1% | ||
| Q1 24 | 3.9% | -115.7% |
| Q4 25 | 1.1% | 0.0% | ||
| Q3 25 | 0.2% | 0.0% | ||
| Q2 25 | 2.6% | 0.0% | ||
| Q1 25 | 1.3% | 0.0% | ||
| Q4 24 | 0.1% | 0.0% | ||
| Q3 24 | 0.7% | 0.9% | ||
| Q2 24 | 0.1% | 0.8% | ||
| Q1 24 | 0.5% | 0.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.45× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SNOA
| Products | $3.9M | 89% |
| Other | $486.0K | 11% |
XOS
Segment breakdown not available.
